IN8bioINAB +0.35%24 9-Day RSI is 45.85 as of Jul. 04, 2026. GuruFocus rates INAB with a GF Score™ of 24/100. Among 1,422 Biotechnology companies, IN8bio ranks better than 60.2% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-04), IN8bio's 9-Day RSI is 45.85.
The industry rank for IN8bio's 9-Day RSI or its related term are showing as below:
INAB's 9-Day RSI is ranked better than 60.2% of 1422
companies
in the Biotechnology industry
Industry Median: 51.47
vs INAB: 45.85
IN8bio (NAS:INAB) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
IN8bio 9-Day RSI Related Terms
INAB vs GDTC, LEXX, TRAW: 9-Day RSI Comparison
For the Biotechnology subindustry, IN8bio's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IN8bio 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IN8bio's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where IN8bio's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IN8bio (INAB) has a 9-Day RSI of 45.85 as of Jul. 04, 2026. According to the industry distribution chart, IN8bio ranks #566 out of 1422 companies in the Biotechnology industry, placing it in the top 39.8%.
Is IN8bio's 9-Day RSI too high?
IN8bio's current 9-Day RSI is 45.85. The Biotechnology industry median 9-Day RSI is 51.47. IN8bio's value of 45.85 is 10.9% below this industry median. Based on the distribution chart, IN8bio ranks #566 out of 1422 companies in the Biotechnology industry, which is above the industry midpoint. Overall, IN8bio has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does IN8bio's 9-Day RSI compare to GDTC and LEXX?
According to the Biotechnology industry distribution chart, IN8bio ranks #566 out of 1422 companies for 9-Day RSI. This puts IN8bio in the upper half of its industry. The industry median 9-Day RSI is 51.47. IN8bio's value of 45.85 is 10.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 51.47, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IN8bio's current 9-Day RSI of 45.85 is 10.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 51.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IN8bio's current 9-Day RSI is 45.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IN8bio stock overvalued right now?
IN8bio (INAB) has a current 9-Day RSI of 45.85. The current 9-Day RSI is 45.85 and 10.9% below the Biotechnology industry median of 51.47. IN8bio's overall GF Score™ is 24/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For IN8bio (INAB), the current 9-Day RSI is 45.85 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
24GF Score
Get the complete analysis for INAB
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INAB has been successfully added to your 